Cargando…

Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma

The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma patients has been evolving recently. Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected to benefit more from the treatment approach. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Machiraju, Devayani, Schäfer, Sarah, Hassel, Jessica C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707626/
https://www.ncbi.nlm.nih.gov/pubmed/34947849
http://dx.doi.org/10.3390/life11121318
_version_ 1784622482186043392
author Machiraju, Devayani
Schäfer, Sarah
Hassel, Jessica C.
author_facet Machiraju, Devayani
Schäfer, Sarah
Hassel, Jessica C.
author_sort Machiraju, Devayani
collection PubMed
description The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma patients has been evolving recently. Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected to benefit more from the treatment approach. However, in contrast to this hypothesis, recent studies in patients with metastatic melanoma have demonstrated that immunotherapy, especially with anti-PD1 treatment, is less effective in patients below 65 years, on average, with significantly lower responses and reduced overall survival compared to patients above 65 years of age. Besides, data on young patients are even more sparse. Hence, in this review, we will focus on age-dependent differences in the previously described resistance mechanisms to the treatment and discuss the development of potential combination treatment strategies for enhancing the anti-tumor efficacy of anti-PD1 or PDL1 treatment in young melanoma patients.
format Online
Article
Text
id pubmed-8707626
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87076262021-12-25 Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma Machiraju, Devayani Schäfer, Sarah Hassel, Jessica C. Life (Basel) Review The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma patients has been evolving recently. Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected to benefit more from the treatment approach. However, in contrast to this hypothesis, recent studies in patients with metastatic melanoma have demonstrated that immunotherapy, especially with anti-PD1 treatment, is less effective in patients below 65 years, on average, with significantly lower responses and reduced overall survival compared to patients above 65 years of age. Besides, data on young patients are even more sparse. Hence, in this review, we will focus on age-dependent differences in the previously described resistance mechanisms to the treatment and discuss the development of potential combination treatment strategies for enhancing the anti-tumor efficacy of anti-PD1 or PDL1 treatment in young melanoma patients. MDPI 2021-11-30 /pmc/articles/PMC8707626/ /pubmed/34947849 http://dx.doi.org/10.3390/life11121318 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Machiraju, Devayani
Schäfer, Sarah
Hassel, Jessica C.
Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
title Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
title_full Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
title_fullStr Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
title_full_unstemmed Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
title_short Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
title_sort potential reasons for unresponsiveness to anti-pd1 immunotherapy in young patients with advanced melanoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707626/
https://www.ncbi.nlm.nih.gov/pubmed/34947849
http://dx.doi.org/10.3390/life11121318
work_keys_str_mv AT machirajudevayani potentialreasonsforunresponsivenesstoantipd1immunotherapyinyoungpatientswithadvancedmelanoma
AT schafersarah potentialreasonsforunresponsivenesstoantipd1immunotherapyinyoungpatientswithadvancedmelanoma
AT hasseljessicac potentialreasonsforunresponsivenesstoantipd1immunotherapyinyoungpatientswithadvancedmelanoma